Coinfection withStrongyloidesand SARS-CoV-2: protocol for a systematic review

Abstract

AbstractRationale for the reviewCOVID-19 treatment can worsen parasitic disease in patients with coinfection. Consequently, there is a need to investigate the infection with SARS-CoV-2 andStrongyloides. We aim to systematically review clinical and laboratory features of COVID-19 andStrongyloidescoinfection, to investigate possible interventions and outcomes in this pathology. Also, we aim to identify difficulties in managing the parasitic disease manifestations in this context and to emphasize research gaps requiring further attention.MethodsWe will search two electronic databases – LitCOVID, and WHO COVID-19 and will include studies on SARS-CoV-2 andStrongyloidescoinfection. We will adapt the WHO-UMC system for standardized case causality assessment to evaluate if using corticosteroids or other immunosuppressive drugs in COVID-19 patients determined acute strongyloidiasis manifestations.Expected resultsWe will present the evidence in three distinct packages: study description, methodological quality assessment and data extracted. We will summarize the evidence and will draw conclusions as to the quality of the evidence.